You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Claims for Patent: 8,911,737

✉ Email this page to a colleague

Summary for Patent: 8,911,737

Title:	Methods of administering anti-TNFα antibodies
Abstract:	Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Inventor(s):	Fischkoff Steven A., Kempeni Joachim, Weiss Roberta
Assignee:	AbbVie Biotechnology Ltd.
Application Number:	US14256886

Details for Patent 8,911,737

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,911,737	2034-04-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,911,737	2034-04-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,911,737	2034-04-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	8,911,737	2034-04-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	8,911,737	2034-04-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,911,737

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	200308861	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	02100330	⤷ Get Started Free
United States of America	9546212	⤷ Get Started Free
United States of America	9073987	⤷ Get Started Free
United States of America	9017680	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.